An open label study to assess the effect of FOLFIRI [fluorouracil, folinic acid, irinotecan] plus Avastin [bevacizumab] and cetuximab on progression-free survival in patients with previously untreated metastatic colorectal cancer.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Irinotecan
Indications Colorectal cancer
Focus Therapeutic Use
Sponsors Roche

Most Recent Events

27 Jul 2018 Planned initiation date changed from 1 Feb 2008 to 1 Dec 2007.
23 Aug 2016 Status changed from discontinued to withdrawn prior to enrolment.
18 Jun 2008 Status changed from initiated to discontinued according to Roche.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight